Navigation Links
Novus Biologicals Hires David Eansor to Lead New Corporate-Development Effort
Date:1/24/2013

LITTLETON, Colo., Jan. 24, 2013 /PRNewswire/ -- Novus Biologicals LLC, a leading provider of antibodies and reagents to the life science research community, has hired David Eansor to lead a new corporate-development effort.

Eansor, a 13-year veteran in the life science market who was most recently the president of Thermo Fisher Scientific's bioscience division, joined Novus in January as senior vice-president of corporate development. In this new role, Eansor is tasked with accelerating Novus' already impressive growth through a combination of organic investments, licensing and acquisitions of complementary products and capabilities.

"I'm thrilled to join Novus, and for the opportunity to create new growth platforms for this innovative company," Eansor said. "I have watched Novus grow from a niche player to a leader in its space, and I've always been impressed with its commitment to scientific research and outstanding customer service."

"We are so pleased to have an executive of David's caliber join our team, and look forward to many stellar contributions as he expands this critical corporate-development function for us," added Karen Padgett , Novus' founder and chief executive.

Before becoming president of the bioscience division of Thermo Fisher , a publicly traded company, Eansor served as president of the life science research division, acquiring three businesses during his tenure.

Prior to that, he was president of Cambrex Bioproducts, another life science research business focused on cell biology. Eansor also spent 19 years with R.P Scherer Corp., a contract pharmaceutical drug-delivery manufacturer which was acquired by Cardinal Health. He holds a degree in chemistry from the University of Western Ontario as well as a bachelor of commerce and an MBA from the University of Windsor, also in Ontario, Canada.

About Novus

Novus Biologicals is a leading digital marketing-driven, life science company that supplies antibodies and reagents to the $6 billion global proteomics market.  Novus is known for its breadth of quality antibodies and reagents that are well recognized by its global customer base.  Based in Littleton, CO, the company was founded in 1996 to license, produce and market antibodies to support niche and emerging areas of research.  Now Novus is a global enterprise with a catalog of 180,000 products sold in 60 countries, mainly through its Web site. Novus is backed by Mainsail Partners, a San Francisco growth-equity firm, and has additional offices in Ontario, Canada and Cambridge, UK.

CONTACT

Karen Padgett , President and CEO

Novus Biologicals, LLC

Karen@novusbio.com

303-730-1950

www.novusbio.com


'/>"/>
SOURCE Novus Biologicals LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
2. PhoenixSongs Biologicals, Inc. Announces Enhanced Neural Lineage-specific Cell Culture Media Products Release
3. PathoGenetix Hires Food Safety Testing Expert John W. Czajka as Vice President of Business Development
4. Ganeden Biotech Hires New Marketing Manager
5. Provia Labs Hires Vice President of International Business Development to Expand Global Distribution for its Stem Cell Banking Service and Biobanking Products
6. Ernst & Young LLP Bolsters Fraud Investigation & Dispute Services with New Hires and Promotions
7. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
8. Textile Company PurThread Technologies Opens Headquarters in Durham, North Carolina and Hires New Senior Staff
9. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
10. Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer
11. David Smith Named Vice President of Operations for HealthTell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
Breaking Biology Technology:
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
Breaking Biology News(10 mins):